Home›Trial›NCT04372108
🔬NCT04372108RECRUITING

A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis

Study Summary

The purpose of this study is to estimate and compare the incidence of overall malignancy, serious infection, and opportunistic infections between new users of ustekinumab and new users of other biologic therapies among adult participants with Crohn's disease (CD) or ulcerative colitis (UC).

Conditions
Crohn DiseaseColitis, Ulcerative
Interventions / Drugs
UstekinumabOther Biologic Therapies
View on ClinicalTrials.gov ↗
Sponsor
JNJ
Johnson & Johnson
Diversified Pharma
C60/100
Study Details
Enrollment1056 participants
Primary Completion—
Lead SponsorJanssen Scientific Affairs, LLC
Data Retrieved2026-04-11 02:55:31.549902+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.